Naslov
Pharmacotherapy of heart failure in light of the new European guidelines

Autori
Zaputović, Luka

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, pp prezentacija, znanstveni

Izvornik
8th Croatian Congress of Pharmacology with international participation. Final Programme and Abstract Book / - Split : Hrvatsko farmaceutsko društvo, 2016, 24-24

Skup
8th Croatian Congress of Pharmacology with international participation

Mjesto i datum
Split, Hrvatska, 15.09.2016. - 18.09.2016

Vrsta sudjelovanja
Plenarno

Vrsta recenzije
Domaća recenzija

Ključne riječi
heart failure; pharmacological treatment; guidelines

Sažetak
Heart failure (HF) is a clinical syndrome characterized by the symptoms and signs of abnormal heart function and favorable response to treatment. It can be caused by any disease that provokes structural, mechanical or electrical abnormality of the heart. The prevalence of HF is 2% of the adult population in developed countries, rising to 10% among people >70 years of age. Main goals of treatment are to improve functional capacity and quality of life, prevent hospital admissions and reduce mortality. Comprehensive therapeutic approach include optimal treatment of the underlying disease, removal of precipitating factors, treatment of co-morbidities, and control of HF by non-pharmacological measures, pharmacotherapy, devices and surgical treatment. The new 2016 ESC Guidelines for the diagnosis and treatment of HF summarize all available evidence in selecting the best management strategies. Neurohormonal antagonists (ACEIs, MRAs and beta-blockers) improve survival in patients with HFrEF and are recommended for the treatment of every patient, unless contraindicated or not tolerated. A new class of HF drugs, a combination of valsartan and sacubitril (neprilysin inhibitor) (Angiotensin Receptor Neprilysin Inhibitor, ARNI), has recently been shown to be superior to enalapril in reducing the risk of death and HF hospitalization in a large clinical trial. ARNI is recommended to replace ACEIs in HFrEF patients who remain symptomatic despite optimal therapy and who fit these trial criteria. The use of ARBs should be restricted to patients with HFrEF unable to tolerate ACEIs or MRAs. Diuretics are indicated in patients with symptoms and/or signs of congestion.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA